心血管组织肾素-血管紧张素系统研究进展  

Advances in Studies of Cardiovascular Renin angiotensin system

作　　者：唐康[1] 王秋娟[1] 

机构地区：[1]中国药科大学生理学教研室

出　　处：《药学进展》1998年第2期77-83,共7页Progress in Pharmaceutical Sciences

摘　　要：心血管的组织内肾素－血管紧张素系统在心血管疾病的病理发展中起着重要作用。血管紧张素Ⅱ（ＡⅡ）是肾素－血管紧张素系统的关键成分，其除对心脏有短期的正性变力作用外，还有长期的致肥厚与重构作用。心血管局部存在三条ＡⅡ生成途径：胃促胰酶（ｃｈｙｍａｓｅ，Ｃｈｙ）途径、血管紧张素Ⅰ转化酶（ａｎｇｉｏｔｅｎｓｉｎｃｏｎｖｅｒｔｉｎｇｅｎｚｙｍｅ，ＡＣＥ）途径和一种被称为Ｎａｆａｍｏｓｔａｔ敏感的途径。由这些途径生成的ＡⅡ都参与缺血、缺氧时心血管的病理变化。近来发现ＡＴ２受体介导抗增殖效应，而ＡＴ１受体拮抗剂逆转心血管肥厚的作用机制可能与此有关。Tissue renin angiotensin system(RAS)existing in heart and blood vessels plays an important role in pathological development of cardiovascular disease. Locally produced angiotensin Ⅱ(Ang Ⅱ) is one of the critical components in the tissue RAS. AngⅡ has not only short term direct cardiac actions including increased contractility,but also long term effects on structural remodelling and myocardial hypertrophy.There seem to be three Ang Ⅱ forming pathways in humans :chymace dependent,angiotensin coverting enzyme (ACE) dependent and nafamostat sensitive Ang Ⅱ formation. And all are involved in the pathological changes occurred in hypoxic or ischaemic hearts or blood vessels. Recent data suggest that AT 2 receptor mediates growth inhibitory action, it may be one mechanism of AT 1 receptor antagonists induced regression of cardiac hypertrophy.

关 键 词：心血管疾病 病理 tissueRAS ACE AT1受体拮抗剂 

分 类 号：R540.2[医药卫生—心血管疾病] R972[医药卫生—内科学]